Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing to limit alcohol intake to 3 or less beverages per day~* Patient agrees to use only acetaminophen/paracetamol for breakthrough pain~Exclusion Criteria:~* Patient has other inflammatory arthritis (e.g. lupus). Patient has had major surgery or donated or lost 1 unit of blood in the last 4 weeks~* Patient has a history of drug or alcohol abuse in the last 2 years~* Patient has had a vaccine (with a live or attenuated virus) in the last two weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone 15 mg (Type: EXPERIMENTAL): Prednisone 15 mg tablets once daily for 15 days
- Placebo 15 mg (Type: PLACEBO_COMPARATOR): Prednisone 15 mg placebo tablets once daily for 15 days
- Prednisone 7.5 mg (Type: EXPERIMENTAL): Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis.
- Placebo 7.5 mg (Type: PLACEBO_COMPARATOR): Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).